Drug Trial Radar · NCT05677971
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
160
Planned (sponsor's estimate)
Start
Mar 6, 2023
Primary completion
Jan 17, 2029
Study completion Dec 12, 2031
Sponsor
- Lead sponsor
- TakedaTakeda (TAK)
- Sponsor type
- Industry
- Collaborators
- Takeda Development Center Americas, Inc.
- First posted
- Jan 10, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics), to learn if fazirsiran reduces other liver injury (inflammation) and the abnormal Z-AAT protein in the liver, to get information on how the body processes fazirsiran (called pharmacokinetics), to test how well fazirsiran works compared with a placebo in improving measures of liver scarring including imaging and liver biomarkers (substances in the blood that the body normally makes and help show if liver function is improving, staying the same, or getting worse) as well as to check for side effects in participants treated with fazirsiran compared with those who received placebo. Participants will either receive fazirsiran or placebo. Liver biopsies, a way of collecting a small tissue sample from the liver, will be taken twice during this study.
Conditions
- Alpha1-Antitrypsin Deficiency
Interventions
Fazirsiran InjectionDrug
Participants will receive fazirsiran 200 mg/ml SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
PlaceboOther
Participants will receive placebo (sterile normal saline \[0.9% NaCl\]) SC injection on Day 1, at Week 4, and Q12 W thereafter up to Week 196.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduction From Baseline of at Least 1 Stage of Histologic Fibrosis (METAVIR Staging) in the Centrally Read Liver Biopsy at Week 106 in AATD-LD With METAVIR Stage F2 and F3 FibrosisTime frame: Baseline, Week 106
Locations
89 sites in 19 countries. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
St. Joseph's Hospital and Medical Center
Phoenix, Arizona · Recruiting
Mayo Clinic
Phoenix, Arizona · Recruiting
University of Arizona Thomas D. Boyer Liver Institute
Tucson, Arizona · Withdrawn
Gastroenterology & Liver Institute
Escondido, California · Withdrawn
University of California San Diego, Altman Clinical and Translational Institute
La Jolla, California · Recruiting
UCLA Pulmonary and Critical Care
Los Angeles, California · Recruiting
Stanford University
Palo Alto, California · Recruiting
University of California Benioff Children's Hospital
San Francisco, California · Recruiting
Peak Gastroenterology Associates, PC
Colorado Springs, Colorado · Recruiting
University of Florida
Gainesville, Florida · Recruiting
Schiff Center for Liver Diseases/University of Miami
Miami, Florida · Recruiting
Children's Healthcare of Atlanta
Atlanta, Georgia · Withdrawn
Indiana University School of Medicine - Indianapolis
Indianapolis, Indiana · Recruiting
University of Iowa Hospitals and Clinics
Iowa City, Iowa · Recruiting
Ochsner Medical Center
New Orleans, Louisiana · Recruiting
University of Maryland Medical Center
Baltimore, Maryland · Recruiting
Brigham and Womens Hospital
Boston, Massachusetts · Recruiting
Boston Medical Center
Boston, Massachusetts · Recruiting
University of Michigan Hospital
Ann Arbor, Michigan · Recruiting
Henry Ford Medical Center - Columbus
Novi, Michigan · Recruiting
Mayo Clinic - PPDS
Rochester, Minnesota · Recruiting
Cardinal Glennon Children's Hospital
St Louis, Missouri · Recruiting
Washington University School of Medicine in St. Louis
St Louis, Missouri · Recruiting
NYU Langone Health
New York, New York · Recruiting
Morgan Stanley Childrens Hospital of New York Presbyterian (CHONY) - PIN
New York, New York · Withdrawn
Columbia University Irving Medical Center
New York, New York · Recruiting
University Hospitals Cleveland Medical Center
Cleveland, Ohio · Recruiting
Penn State Health Milton S. Hershey Medical Center
Hershey, Pennsylvania · Recruiting
Temple University Hospital
Philadelphia, Pennsylvania · Recruiting
Medical University of South Carolina
Charleston, South Carolina · Recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
Texoma Liver Center
Denison, Texas · Recruiting
Baylor College of Medicine Medical Center
Houston, Texas · Recruiting
The Texas Liver Institute
San Antonio, Texas · Recruiting
Bon Secours St. Mary's Hospital
Richmond, Virginia · Recruiting
VCU Medical Center North Hospital
Richmond, Virginia · Recruiting
Royal Adelaide Hospital
Adelaide, South Australia, Australia · Withdrawn
St Vincents Hospital Melbourne - PPDS
Fitzroy, Victoria, Australia · Recruiting
LKH-Universitätsklinikum Graz
Graz, Austria · Recruiting
Showing 40 of 89 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.